November 26, 2015
Recommended Topic Related To:

Megace ES

"The number of pregnant and breastfeeding women in Malawi with HIV who started life-saving antiretroviral treatment increased by more than 700 percent in one year, according to a study in CDC's Morbidity and Mortality Weekly Report. The "...

Megace ES

How Supplied


Megace® ES (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS).


The recommended adult initial dosage of Megace® ES (megestrol acetate) oral suspension is 625 mg/day (5 mL/day or one teaspoon daily). Please refer to the table below for correct dosing and administration. Shake container well before using.

  Megace® ES
Oral Suspension
Megace® and other
megestrol acetate oral suspensions
mg/mL 125 mg/mL 40 mg/mL
Daily Dose
625 mg 800 mg
Daily VolumeIntake 5 mL 20 mL
(teaspoon) Megace-es (Megestrol acetate)  teaspoon (dosing cup) Megace-es (Megestrol acetate)  dosing cup
Formulation Concentrated formula Regular formula

In clinical trials evaluating different dose schedules, daily doses of 400 and 800 mg/day of megestrol acetate oral suspension (800 mg/20 mL equivalent to 625 mg/5 mL of Megace® ES formula) were found to be clinically effective.


Megace® ES (megestrol acetate) oral suspension is a concentrated formula available as a milky white, lemon-lime flavored oral suspension containing 125 mg of megestrol acetate per mL.

NDC 49884-949-69 Bottles of 150 mL (5 fl. oz.)
NDC 49884-949-52 Unit Dose Bottles of 5 mL (0.17 fl. Oz.)-Institutional Use Only



Store Megace® ES (megestrol acetate) oral suspension between 15°-25° C (59°-77° F) and dispense in a tight container. Protect from heat.

Special Handling

Health Hazard Data

There is no threshold limit value established by OSHA, NIOSH, or ACGIH.

Exposure or overdose at levels approaching recommended dosing levels could result in side effects described above (see WARNINGS and ADVERSE REACTIONS sections). Women at risk of pregnancy should avoid such exposure.

Manufactured by:
Spring Valley, New York 10977
Megace® is a registered trademark of Bristol-Myers Squibb Company licensed to Par Pharmaceutical, Inc.
FDA rev date: 8/12/2008.

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 8/28/2008

How Supplied

Megace ES - User Reviews

Megace ES User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Megace ES sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

WebMD Daily

Get breaking medical news.